These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cost-Effectiveness Analysis of Fluocinolone Acetonide Intravitreal (FAI) Implant for Chronic Noninfectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS) in China. Mao X; Dai Z; Yang J; Wu Y; Xie F; Lu Y; Yu J; Chang F; Lu Y Ophthalmol Ther; 2024 Jun; 13(6):1757-1772. PubMed ID: 38676875 [TBL] [Abstract][Full Text] [Related]
6. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. Moll-Udina A; Hernanz I; Sainz-de-la-Maza M; Pelegrín L; Coelho-Borges AI; Pazos M; Adán A; Llorenç V Int Ophthalmol; 2023 Nov; 43(11):4181-4195. PubMed ID: 37698661 [TBL] [Abstract][Full Text] [Related]
8. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India. Biswas J; Tyagi M; Agarwal M; Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419 [TBL] [Abstract][Full Text] [Related]
9. Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis. Babel AT; Chin EK; Almeida DRP Int Med Case Rep J; 2022; 15():665-669. PubMed ID: 36444172 [TBL] [Abstract][Full Text] [Related]
11. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
12. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]
14. The 0.19-mg Fluocinolone Acetonide Implant for the Treatment of Diabetic Macular Edema: An Expert Consensus. Kolomeyer AM; Eichenbaum DA; Kiernan DF; Suñer IJ; Hariprasad SM Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):166-173. PubMed ID: 36944067 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. Mahmud H; Ahmad TR; Gonzales JA; Stewart JM Ocul Immunol Inflamm; 2023 Oct; 31(8):1603-1607. PubMed ID: 35793136 [TBL] [Abstract][Full Text] [Related]
16. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262 [TBL] [Abstract][Full Text] [Related]
18. Development of a Core Outcome Set for Clinical Trials in Non-infectious Uveitis of the Posterior Segment. Tallouzi MO; Mathers JM; Moore DJ; Bucknall N; Calvert MJ; Murray PI; Denniston AK; Ophthalmology; 2021 Aug; 128(8):1209-1221. PubMed ID: 33515595 [TBL] [Abstract][Full Text] [Related]
19. Single Institution Experience of Intravitreal 0.18-mg Fluocinolone Acetonide Implant for Noninfectious Uveitis. Reddy AK; Pecen PE; Patnaik JL; Palestine AG Ophthalmol Retina; 2023 Jan; 7(1):67-71. PubMed ID: 35820567 [TBL] [Abstract][Full Text] [Related]